Ixekizumab for treatment of psoriasis

Expert Review of Clinical Immunology

Volumn 11, Issue 4, 2015, Pages 435-442

  Dyring Andersen, Beatrice ^a   Skov, Lone ^a   Zachariae, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

IL 17A; IL 17F; IL 22; ixekinumab; psoriasis

Indexed keywords

BRODALUMAB; HOMODIMER; IMMUNOGLOBULIN G4; INTERLEUKIN 17; IXEKIZUMAB; PLACEBO; PREDNISOLONE; SECUKINUMAB; INTERLEUKIN 17 RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; INJECTION SITE REACTION; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PSORIASIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SKIN;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PSORIASIS; RECEPTORS, INTERLEUKIN-17; SKIN;

EID: 84924995972     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1023295     Document Type: Article

References (47)

1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133(2):377-85
2. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine functional properties. Annu Rev Immunol 1989;7:145-73
3. Rouvier E, Luciani MF, Matteí MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150(12): 5445-56
4. Res PCM, Piskin G, De Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010; 5(11):e14108
5. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 2011;35(4): 596-610
6. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011;23(5):613-19
7. Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 2013;190(5):2252-62
8. Toy D, Kugler D, Wolfson M, et al. Cutting Edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177(1):36-9
9. Yao Z, Spriggs MK, Derry JM, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997; 9(11):794-800
10. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008;41(2):92-104
11. Van Beelen AJ, Teunissen MBM, Kapsenberg ML, De Jong EC. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007;7(5):374-81
12. Teunissen MBM, Koomen CW, De Waal Malefyt R, et al. Interleukin-17 and interferon-g synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111(4):645-9
13. Koczulla R, Von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111(11):1665-72
14. Braff M, Gallo R. Antimicrobial peptides: an essential component of the skin defensive barrier. Antimicrob Pept Hum Dis 2006;306:91-110
15. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159(5):1092-102
16. Cho K-A, Suh JW, Lee KH, et al. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1b by keratinocytes via the ROS-NLRP3-caspase- 1 pathway. Int Immunol 2012;24(3):147-58
17. Kim T-G, Jee H, Fuentes-Duculan J, et al. Dermal clusters of mature dendritic cells and T cells are associated with the ccl20/ccr6 chemokine system in chronic psoriasis. J Invest Dermatol 2014;134(5):1462-5
18. Liang SC, Tan X-Y, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203(10):2271-9
19. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21(2):241-54
20. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150(3):407-15
21. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183(6): 2593-603 cells
22. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T Cell Trafficking and Development by IFN-g: mechanism and pathological relevance in psoriasis. J Immunol 2008;181(7):4733-41
23. El-Moaty Zaher HA, El-Komy MHM, Hegazy RA, et al. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J Am Acad Dermatol 2013;69(5):840-2
24. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128(5): 1207-11
25. Pène J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008; 180(11):7423-30
26. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199(1):125-30
27. Toichi E, Torres G, McCormick TS, et al. An Anti-IL-12p40 antibody down-regulates type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis. J Immunol 2006;177(7): 4917-26
28. Griffiths CEM, Strober BE, van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28
29. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517
30. Tham L-S, Tang C-C, Choi S-L, et al. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. J Clin Pharmacol 2014;54(10):1117-24
31. Genovese MC, Greenwald M, Cho C-S, et al. A Phase II. Randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66(7):1693-704
32. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130(1):145-54.e9
33. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13): 1190-9
34. Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014;71(6):1176-82
35. Genovese MC, Van Den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62(4):929-39
36. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124(5):1022-30.e395
37. Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatology Venereol 2014. [Epub ahead of print
38. Puel A, Cypowyj S, Bustamante J, et al. Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity. Science 2011; 332(6025):65-8
39. Boisson B, Wang C, Pedergnana V, et al. An act1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013;39(4):676-86
40. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14(3):275-81
41. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung cxc chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194(4):519-28
42. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17a and-17f in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009;30(1):108-19
43. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
44. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, doubleblind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168(2):412-21
45. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370(24):2295-306
46. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014;170:261-73
47. Fernandez-Flores A. The role of IgG4 in cutaneous pathology. Rom J Morphol Embryol 2012;53(2):221-31